FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:1615-1616 April 10, 2008 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET, NCT00153101 [ClinicalTrials.gov] ), reported by Yusuf et al.¹ in this issue of the Journal, has important lessons for clinical practice and also illustrates the complexities of designing, conducting, analyzing, and interpreting trials comparing new treatments that act in a manner similar to that of established therapies. As the fourth and largest comparative trial, the ONTARGET study confirms, beyond doubt, that angiotensin-receptor blockers (ARBs) are not better than angiotensin-converting–enzyme (ACE) inhibitors at reducing fatal and nonfatal cardiovascular events. Of course, physicians and patients might still choose to use an . . . [Full Text of this Article]

Source Information

This article (10.1056/NEJMe0801925) was published at www.nejm.org on March 31, 2008.

From the British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland.

This article has been cited by other articles:

• Kaplan, N. M. (2008). Recent Clinical Trials: The Good, the Bad, and the Misleading. Hypertension 52: 608-609 [Full Text]  
• Buchner, N., Banas, B., Kramer, B. K., Messerli, F. H., Bangalore, S., Ram, V. S., McMurray, J. J.V. (2008). Telmisartan, ramipril, or both in patients at high risk of vascular events.. NEJM 359: 426-427 [Full Text]